Catalyst
Slingshot members are tracking this event:
MacroGenics (MGNX) to complete Phase 3 study of Margetuximab in treatment of HER2+ Metastatic Breast Cancer in 2018
- Source Link:
- http://www.macrogenics.com/margetuximab-anti-her2/
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MGNX |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 23, 2018
Occurred Source:
http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-announces-continuation-sophia-study-margetuximab
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Margetuximab, Metastatic Breast Cancer, Her2-positive Breast Cancer, Phase 3 Study, Trastuzumab
